Randomized trial of rivaroxaban versus warfarin in the evaluation of progression of coronary atherosclerosis

Am Heart J. 2018 Dec:206:127-130. doi: 10.1016/j.ahj.2018.08.007. Epub 2018 Aug 24.

Abstract

Warfarin, a vitamin K antagonist, is associated with systemic vascular calcification. We evaluated whether rivaroxaban (a direct oral factor Xa inhibitor with no interaction with vitamin K) will slow the progression in coronary plaque volumes compared with warfarin in patients with nonvalvular atrial fibrillation using coronary computed tomography angiography.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Anticoagulants / administration & dosage
  • Atherosclerosis / diagnosis
  • Atherosclerosis / drug therapy*
  • Coronary Angiography
  • Coronary Artery Disease / diagnosis
  • Coronary Artery Disease / drug therapy*
  • Dose-Response Relationship, Drug
  • Factor Xa Inhibitors / administration & dosage
  • Female
  • Humans
  • Male
  • Middle Aged
  • Randomized Controlled Trials as Topic / methods*
  • Rivaroxaban / administration & dosage*
  • Warfarin / administration & dosage*

Substances

  • Anticoagulants
  • Factor Xa Inhibitors
  • Warfarin
  • Rivaroxaban